Discovery of novel polyamine analogs with anti-protozoal activity by computer guided drug repositioning
- 18 February 2016
- journal article
- research article
- Published by Springer Nature in Journal of Computer-Aided Molecular Design
- Vol. 30 (4) , 305-321
Abstract
Chagas disease is a parasitic infection caused by the protozoa Trypanosoma cruzi that affects about 6 million people in Latin America. Despite its sanitary importance, there are currently only two drugs available for treatment: benznidazole and nifurtimox, both exhibiting serious adverse effects and limited efficacy in the chronic stage of the disease. Polyamines are ubiquitous to all living organisms where they participate in multiple basic functions such as biosynthesis of nucleic acids and proteins, proliferation and cell differentiation. T. cruzi is auxotroph for polyamines, which are taken up from the extracellular medium by efficient transporters and, to a large extent, incorporated into trypanothione (bis-glutathionylspermidine), the major redox cosubstrate of trypanosomatids. From a 268-compound database containing polyamine analogs with and without inhibitory effect on T. cruzi we have inferred classificatory models that were later applied in a virtual screening campaign to identify anti-trypanosomal compounds among drugs already used for other therapeutic indications (i.e. computer-guided drug repositioning) compiled in the DrugBank and Sweetlead databases. Five of the candidates identified with this strategy were evaluated in cellular models from different pathogenic trypanosomatids (T. cruzi wt, T. cruzi PAT12, T. brucei and Leishmania infantum), and in vitro models of aminoacid/polyamine transport assays and trypanothione synthetase inhibition assay. Triclabendazole, sertaconazole and paroxetine displayed inhibitory effects on the proliferation of T. cruzi (epimastigotes) and the uptake of putrescine by the parasite. They also interfered with the uptake of others aminoacids and the proliferation of infective T. brucei and L. infantum (promastigotes). Trypanothione synthetase was ruled out as molecular target for the anti-parasitic activity of these compounds.Keywords
Funding Information
- Argentinean National Agency of Scientific and Technical Promotion (PICT 2013-0520)
- MERCOSUR Structural Convergence Fund (COF 03/11)
- Universidad Nacional de La Plata (AR) (X-730)
This publication has 66 references indexed in Scilit:
- Directory of Useful Decoys, Enhanced (DUD-E): Better Ligands and Decoys for Better BenchmarkingJournal of Medicinal Chemistry, 2012
- Evaluation of Arylimidamides DB1955 and DB1960 as Candidates against Visceral Leishmaniasis and Chagas' Disease: In Vivo Efficacy, Acute Toxicity, Pharmacokinetics, and Toxicology StudiesAntimicrobial Agents and Chemotherapy, 2012
- The Trypanocidal Activity of Amidine Compounds Does Not Correlate with Their Binding Affinity to Trypanosoma cruzi Kinetoplast DNAAntimicrobial Agents and Chemotherapy, 2011
- Polyamine homoeostasis as a drug target in pathogenic protozoa: peculiarities and possibilitiesBiochemical Journal, 2011
- Gitools: Analysis and Visualisation of Genomic Data Using Interactive Heat-MapsPLOS ONE, 2011
- DrugBank 3.0: a comprehensive resource for 'Omics' research on drugsNucleic Acids Research, 2010
- A high‐affinity putrescine‐cadaverine transporter from Trypanosoma cruziMolecular Microbiology, 2010
- In Vitro and In Vivo Studies of the Trypanocidal Activity of a Diarylthiophene Diamidine against Trypanosoma cruziAntimicrobial Agents and Chemotherapy, 2008
- Validation of spermidine synthase as a drug target in African trypanosomesBiochemical Journal, 2007
- Drug repositioning: identifying and developing new uses for existing drugsNature Reviews Drug Discovery, 2004